PhaseBio Announces Presentation of PB2452 Data at ESC Congress 2019
August 26 2019 - 8:00AM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of novel therapies for orphan diseases, today
announced that pharmacodynamic data from the Phase 1 clinical trial
of PB2452, a novel reversal agent for the antiplatelet drug
ticagrelor, have been selected for oral presentation at ESC
Congress 2019, being held August 31 - September 4, 2019, at the
Expo Porte de Versailles in Paris, France.
Presentation details are as follows:
Title: Evaluation of the Pharmacodynamics of a
Ticagrelor Reversal Agent PB2452Session: New
Developments in Anti-Thrombotic Drug TherapyDate /
Time: Sunday, September 1, 17:32 - 17:50 GMT/ 11:32 –
11:50 AM EDTLocation: Reykjavik - Village
2Presenter: Lisa K. Jennings, Ph.D., University of
Tennessee Health Science Center
Additional information can be found on the ESC
Congress website here.
About PB2452
PB2452 is a novel, recombinant, human monoclonal
antibody antigen-binding fragment, or Fab, designed to reverse the
antiplatelet activity of ticagrelor in major bleeding and urgent
surgery situations. In a Phase 1 clinical trial, PB2452
demonstrated the potential to bring life-saving therapeutic benefit
through immediate and sustained reversal of ticagrelor’s
antiplatelet activity, mitigating concerns regarding bleeding risks
associated with the use of antiplatelet drugs. The Phase 1 clinical
trial of PB2452 in healthy volunteers was published in the New
England Journal of Medicine in March 2019.1 In April
2019, PB2452 received Breakthrough Therapy designation from
the U.S. Food and Drug Administration (“FDA”).
Breakthrough Designation may be granted by FDA when
preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapy. In the
first quarter of 2020, PhaseBio plans to initiate a single pivotal
Phase 3 clinical trial of PB2452 which will support a Biologics
License Application for both major bleeding and surgery
indications. There are currently no approved reversal agents for
ticagrelor or any other antiplatelet drugs.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies to treat orphan diseases,
with an initial focus on cardiopulmonary disorders. The company’s
lead development candidate is PB2452, a novel reversal agent for
the antiplatelet therapy ticagrelor. PhaseBio is also leveraging
its proprietary elastin-like polypeptide (“ELP”) technology
platform to develop therapies with the potential for less-frequent
dosing and improved pharmacokinetics. PhaseBio’s second product
candidate PB1046, which is based on ELP, is a once-weekly
vasoactive intestinal peptide receptor agonist for the treatment of
pulmonary arterial hypertension.
PhaseBio is located in Malvern,
PA and San Diego, CA. For more information, please
visit www.phasebio.com.
Investor Contact:
John Sharp PhaseBio Pharmaceuticals, Inc. Chief Financial Officer
(610) 981-6506 john.sharp@phasebio.com
Media Contact: Gina
Cestari 6 Degrees (917) 797-7904 gcestari@6degreespr.com
- Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based
Ticagrelor Reversal Agent in Healthy Volunteers. N Engl J
Med 2019;Mar 17.
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Aug 2024 to Sep 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Sep 2023 to Sep 2024